EU court confirms €60m fine for Teva

19-10-2023

Liz Hockley

EU court confirms €60m fine for Teva

shutterstock_2162525475_jonathan-weiss

Luxemboug court agrees with European Commission that ‘beneficial arrangement’ between Teva and Cephalon delayed generic market entry of sleep disorder drug | Teva and subsidiary Cephalon to pay around €30m each plus costs.


Teva Pharmaceuticals, Cephalon, modafinil, antitrust, EU General Court, patent

LSIPR